Document Detail

The cost effectiveness of palivizumab: a systematic review of the evidence.
MedLine Citation:
PMID:  20653398     Owner:  NLM     Status:  In-Process    
OBJECTIVE: Palivizumab is a prophylactic therapy shown to reduce the number of respiratory syncytial virus (RSV)-related hospitalizations but has a high acquisition cost. The objective was to systematically examine the cost effectiveness of palivizumab in defined infant groups and identify important cost and outcome determinants.
METHODS: Literature searches of MedLine, the Cost-Effectiveness Analysis registry and the UK NHS Economic Evaluation Database (NHS EED) were conducted to identify economic evaluations of palivizumab compared to no prophylactic treatment for RSV prevention in any infant population. Study quality was evaluated using Quality of Health Economic Studies (QHES) criteria and results converted to 2009 CAN$ for comparison.
RESULTS: A total of 23 articles meeting inclusion criteria were identified, including 11 cost-utility analyses (CUAs) and 12 cost-effectiveness analyses (CEAs). Quality of individual analyses was fairly high (range 60-100, median 86). Results ranged from cost dominance for prophylaxis to $3,365,769/QALY depending on population, outcome measures, and input parameters. Base-case and sensitivity-analysis mortality rates varied between studies and influenced results.
CONCLUSIONS: RSV prophylaxis with palivizumab is cost effective in specific groups of high-risk infants, especially those with multiple environmental risk factors. Cost-effectiveness estimates vary between populations and settings and are more positive in those at highest risk for RSV hospitalization.
LIMITATIONS: Direct comparison of the published reports was limited by restriction to English language articles and the varied methodologies, input measures, and populations across the studies reviewed. Although reported currencies were converted to a common unit for comparison, this does not completely account for monetary and inflation differences.
Kelly A Smart; Krista L Lanctôt; Bosco A Paes
Related Documents :
16170298 - Acute encephalopathy associated with respiratory syncytial virus infections in childhoo...
8586738 - Detection of respiratory syncytial virus by reverse transcription-pcr and hybridization...
15185148 - Evaluation of surfactant function at birth determined by the stable microbubble test in...
2011428 - Failure to detect surfactant protein-specific antibodies in sera of premature infants t...
1759138 - Parental grief following the death of an infant--a follow-up over one year.
12239738 - Descriptive epidemiology of anal atresia in hawaii, 1986-1999.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of medical economics     Volume:  13     ISSN:  1941-837X     ISO Abbreviation:  J Med Econ     Publication Date:  2010  
Date Detail:
Created Date:  2010-09-15     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9892255     Medline TA:  J Med Econ     Country:  England    
Other Details:
Languages:  eng     Pagination:  453-63     Citation Subset:  IM    
Medical Outcomes and Research in Economics (MORE®), Sunnybrook Health Sciences Centre and Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The assessment of efficacy of Diascorea alata for menopausal symptom treatment in Taiwanese women.
Next Document:  Economic and clinical contributions of an antimicrobial barrier dressing: a strategy for the reducti...